The Latest Breaking News from rapeutic Goods Administration

Canisters of nitrous oxide, known as "nangs" and linked to the death of a Queensland man, are readily available across Australia. But drug experts disagree on what to do.

The Therapeutic Goods Administration has approved the use of magic mushrooms and ecstasy for mental health treatment.

The Threapeutic Goods Administration is considering whether to reschedule MDMA and psilocybin.

Healthcare workers say they are "gobsmacked" by a shortage of essential treatments for diabetics.

The Therapeutic Goods Administration approves Pfizer's paediatric dose of its COVID vaccine for children aged between six months and five years old.

The Therapeutic Goods Administration has given provisional approval for Pfizer's COVID-19 booster to be used in children aged six months to five years.

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

The Therapeutic Goods Administration will look at limiting the sale of paracetamol over concerns of teenagers overdosing, and there’s a push to ban asylum seekers being handcuffed when being taken to see doctors.